In 2019, the U.S. Food and Drug Administration (FDA) discovered that some ranitidine products contained NDMA impurities at levels higher than what is considered acceptable. Subsequent investigations revealed that NDMA levels could increase over time, particularly when the medication is stored at higher temperatures. As a result, the FDA requested the withdrawal of all ranitidine products from the market in April 2020.
